SCHEMBL24344770

SCHEMBL24344770

COC(=O)c1ccc(OC(=O)N(C)CCN(C)C(=O)OC(C)(C)C)cc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDK2 Q15119 3/20 0.47
CA12 O43570 2/20 0.47
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47
CA7 P43166 2/20 0.47
CA9 Q16790 2/20 0.47
CA14 Q9ULX7 2/20 0.47
PDK4 Q16654 2/20 0.47
MAOB P27338 3/20 0.42
GAA P10253 1/20 0.42
EGFR P00533 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.39
CSNK2A1 P68400 1/20 0.39
NPC1 O15118 2/20 0.39
MAPK1 P28482 2/20 0.39
TP53 P04637 1/20 0.39
MYC P01106 1/20 0.38
MAOA P21397 1/20 0.38
RAB9A P51151 1/20 0.38
ALDH1A1 P00352 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24343456 0.90 PDK2 (0.39) PDK2MAOBRAB9AACHE
SCHEMBL26691712 0.85 PDK2 (0.42) PDK2MAOBEGFRRAB9AACHE
SCHEMBL24344772 0.83 FFAR4 (0.42) PDK2MAOBGAAEGFRSMN1; SMN2
SCHEMBL25725326 0.83 PDK2 (0.40) PDK2MAOBRAB9AACHE
SCHEMBL24344756 0.81 MAPT (0.45) CA1CA2RAB9AALDH1A1
SCHEMBL26691706 0.77 TDP1 (0.43) PDK2SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL25725297 0.75 RAB9A (0.44) PDK2GAASMN1; SMN2RAB9AALDH1A1
SCHEMBL26691721 0.74 KDM4E (0.40) PDK2GAANPC1MAPK1RAB9A
SCHEMBL25725295 0.74 GBA1 (0.46) PDK2SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL18826305 0.74 CA12 (0.65) PDK2CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4457229-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES Byondis B.V. (NL) 2024-11-06 EP disclosed
WO-2023126297-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES BYONDIS B.V. (NL) 2023-07-06 WO disclosed
US-20230144211-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES BYONDIS B.V. (NL) 2023-05-11 US disclosed
EP-4175672-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES Byondis B.V. (NL) 2023-05-10 EP disclosed
US-20220119392-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES BYONDIS B.V. (NL) 2022-04-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230144211-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES DHFR, FOLR1, MTHFD2 PDK2 2853/4885CA12 1260/4885CA1 2964/4885
US-20220119392-A1 ANTIFOLATE LINKER-DRUGS AND ANTIBODY-DRUG CONJUGATES DHFR, FOLR1, MTHFD2 PDK2 2853/4885CA12 1260/4885CA1 2964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.